Jiayan Chen

Jiayan Chen

Auto-generated profile, based on publicly available information

Jiayan Chen

Department of Radiation Oncology Fudan University Shanghai Cancer Center Shanghai China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2019 in Journal of Thoracic Disease
Verified
Journal Article
Open access
PDF file
XXXinyan Xu
Xinyan Xu
LHLyu Huang
Lyu Huang
JCJiayan Chen
Jiayan Chen
JWJunMiao Wen
JunMiao Wen
DLDi Liu
Di Liu
MFMin Fan
Min Fan
Background: The purpose of this study is to develop a radiomics approach to predict brain metastasis (BM) for stage III/IV ALK-positive non-small cell lung cancer (NSCLC) patients. Methods: Patients with ALK-positive III/IV NSCLC from 2014 to 2017 were enrolled retrospectively. Their pretreatment thoracic CT images were collected, and the gross tumor volume (GTV) was defined by two experienced radiation oncologists. An in-house feature extraction code-set was performed based on MATLAB 2015b (Mathworks, Natick, MA, USA) in patients’ CT images to extract features. Patients were randomly divided into training set and test set (4:1) by using createDataPartition function in caret package. A test-retest in RIDER NSCLC dataset was performed to identify stable radiomics features. LASSO Cox regression and a leave-one-out cross-validation were conducted to identify optimal features for the logistic regression model to evaluate the predictive value of radiomics feature(s) for BM. Furthermore, extended validation for the radiomics feature(s) and Cox regression analyses which combined radiomics feature(s) and treatment elements were implemented to predict the risk of BM during follow-up. Results: In total, 132 patients were included, among which 27 patients had pretreatment BM. The median follow-up time was 11.8 (range, 0.1–65.2) months. In the training set, one radiomics feature (W_GLCM_LH_Correlation) showed discrimination ability of BM (P value =0.014, AUC =0.687, 95% CI: 0.551–0.824, specificity =83.5%, sensitivity =57.1%). It also exhibited reposeful performance in the test set (AUC =0.642, 95% CI: 0.501–0.783, specificity =60.0%, sensitivity =83.3%). Those 105 patients without pretreatment BM were divided into stage III (n=57) and stage IV (n=48) groups. The radiomics feature (W_GLCM_LH_Correlation) had moderate performance to predict BM during/after treatment in separate groups (stage III: AUC =0.682, 95% CI: 0.537–0.826, specificity =64.4%, sensitivity =75.0%; stage IV: AUC =0.653, 95% CI: 0.503–0.804, specificity =70.4%, sensitivity =75.0%). Meanwhile, stage III patients could be divided into low risk and high risk groups for BM during surveillance according to Cox regression analysis (log-rank P value =0.021). Conclusions: We identified one wavelet texture feature derived from pretreatment thoracic CT that presented potential in predicting BM in stage III/IV ALK-positive NSCLC patients. This could be beneficial to risk stratification for such patients. Further investigation is necessary to include expanded sample size investigation and external multicenter validation.

1 December 2018 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
JWJunMiao Wen
JunMiao Wen
DLDi Liu
Di Liu
XXXinyan Xu
Xinyan Xu
DCDonglai Chen
Donglai Chen
YCYongbing Chen
Yongbing Chen
MFMin Fan
Min Fan
Background: The aim of this study was to develop and validate reliable nomograms to predict individual overall survival (OS) and cancer-specific survival (CSS) for patients with primary tracheal tumors and further estimate the role of postoperative radiotherapy (PORT) for these entities. Patients and methods: A total of 405 eligible patients diagnosed between 1988 and 2015 were selected from the Surveillance, Epidemiology, and End Results database. All of them were randomly divided into training (n=303) and validation (n=102) sets. For the purpose of establishing nomograms, the Akaike information criterion was employed to select significant prognostic factors in multivariate Cox regression models. Both internal and external validations of the nomograms were evaluated by Harrell’s concordance index (C-index) and calibration plots. Propensity score matching (PSM) method was performed to reduce the influence of selection bias between the PORT group and the non-PORT group. Results: Two nomograms shared common variables including age at diagnosis, histology, N and M stages, tumor size, and treatment types, while gender was only incorporated in the CSS nomogram. The C-indices of OS and CSS nomograms were 0.817 and 0.813, displaying considerable predictive accuracy. The calibration curves indicated consistency between the nomograms and the actual observations. When the nomograms were applied to the validation set, the results remained reconcilable. Moreover, the nomograms showed superiority over the Bhattacharyya’s staging system with regard to the C-indices. After PSM, PORT was not associated with significantly better OS or CSS. Only squamous cell carcinoma (SCC) patients in the PORT group had improved OS compared to non-PORT group. Conclusion: The first two nomograms for predicting survival in patients with primary tracheal tumors were proposed in the present study. PORT seems to improve the prognosis of SCC patients, which needs further exploration.

5 June 2025 in Annals of Medicine
Verified
Journal Article
Open access
HLHuiting Li
Huiting Li
BWBoyan Wang
Boyan Wang
DCDonglai Chen
Donglai Chen
YCYongbing Chen
Yongbing Chen
MFMin Fan
Min Fan
JCJiayan Chen
Jiayan Chen
This study aims to investigate the prognostic value of baseline and absolute changes of inflammatory markers in thymic epithelial tumors (TETs). This real-world study enrolled 147 patients. Inflammatory markers, including baseline and absolute changes of platelet-to-lymphocyte (PLR), platelet-to-monocyte (PMR), lymphocyte-to-monocyte (LMR), and neutrophil-to-lymphocyte ratio (NLR), were retrospectively collected. Survival analysis was conducted using Kaplan–Meier analysis. Lasso and multivariate Cox regression were conducted to assess the relationship between disease-free survival (DFS), overall survival (OS) and inflammatory markers. Predictive nomograms were constructed by variables identified in Cox regression. Higher baseline NLR and PLR, lower baseline LMR and PMR, a greater change in PLR and smaller changes in LMR, PMR, and PNR related to inferior DFS and OS. Multivariate Cox regression identified higher baseline PLR and advanced Masaoka Stage were risk, while higher baseline PMR was protective OS factors. Age, higher baseline PLR, and advanced Masaoka Stage were risk DFS factors. A greater absolute PLR change and metastasis were risk, while a lower absolute PMR change was protective OS factors. Age and a greater absolute PLR change were risk, while a greater absolute LMR change was favorable DFS factors. The present study is the first to reveal the prognostic role of the baseline and absolute changes of inflammatory markers in TETs. The prognostic models based on these inflammatory markers offer promising tools for predicting the prognosis of TET patients.

5 October 2025 in Advanced Science
Verified
Journal Article
Open access
ZWZhenyi Wang
Zhenyi Wang
HHHuanhuan Huang
Huanhuan Huang
KHKaizong Huang
Kaizong Huang
XCXiaowen Cui
Xiaowen Cui
LWLeilei Wu
Leilei Wu
DWDongping Wei
Dongping Wei
Metastasis is the primary challenge in lung cancer treatment. Although proteostasis supports tumor growth, the mechanism by which ubiquitin ligases reprogram chaperone networks to drive metastasis is poorly understood. In this study, it is revealed that DDB1‐CUL4‐associated factor (DCAF12), a substrate receptor for CUL4‐RING ubiquitin ligases, regulates metastatic progression through ubiquitin‐mediated proteostatic reprogramming. DCAF12 depletion suppresses tumor cell migration and stemness in vitro and reduces pulmonary/hepatic metastasis in vivo. Mechanistically, DCAF12 catalyzes the non‐degradative ubiquitination of TRiC/CCT subunits, enhancing chaperonin assembly and folding of cytoskeletal effectors (β‐actin/tubulin) and oncogenic clients (STAT3/Raptor/mLST8), thereby activating the YAP, STAT3, and mTOR pathways. Both genetic knockdown and pharmacological blockade (via HSF1A) of this axis potently inhibit metastasis. Clinically, DCAF12 overexpression is correlated with YAP/STAT3 activation, advanced metastasis, and poor survival. Three key insights are revealed: 1) ubiquitination‐mediated TRiC/CCT regulation as a metastatic switch, 2) DCAF12 as an oncogenic proteostasis hub, and 3) therapeutic potential validated through multimodal targeting. These findings establish the DCAF12‐TRiC/CCT axis as a mechanistically novel target that simultaneously disrupts cytoskeletal dynamics and oncogenic signaling, making it a promising therapeutic strategy for metastatic lung cancer.

20 January 2026 in Advanced Science
Verified
Journal Article
Open access
DWDongping Wei
Dongping Wei
JCJiayan Chen
Jiayan Chen
YXYaping Xu
Yaping Xu
Metastasis, the leading cause of cancer‐related mortality, poses a fundamental proteostatic challenge, requiring rapid and precise proteome remodeling in response to stress. While ubiquitination is linked to protein degradation, our recent work uncovered a non‐canonical, metastasis‐promoting mechanism centered on DCAF12, a substrate receptor of the Cullin 4–RING ubiquitin ligase complex. DCAF12 mediates non‐degradative ubiquitination of TRiC/CCT chaperonin subunits, allosterically activating the chaperonin to enhance its assembly, stability, and folding capacity. This ubiquitination‐dependent activation circuit enables metastatic cells to efficiently fold and stabilize diverse pro‐metastatic proteins, thereby facilitating dynamic proteome reprogramming. Herein, we present the DCAF12–TRiC/CCT axis as a central regulatory component of this adaptive response, explore its evolutionary basis, and propose DCAF12 as a prototype for a broader class of “DCAFome” regulators of chaperone function. This mechanistic understanding establishes a direct rationale for therapeutically targeting this axis to disrupt adaptive proteostasis. Moreover, we outline a therapeutic paradigm termed “proteostatic stress creation.” This framework encompasses a spectrum of strategies, from precision protein–protein interaction inhibitors to state‐selective degraders of DCAF12 or its ubiquitinated chaperonin subunits. These approaches can potentially disrupt the DCAF12–TRiC/CCT axis, thereby undermining the proteostatic resilience that sustains advanced cancers.